


PHARMACEUTICAL 2022

Abbott

ABBOTT LABORATORIES Rank 20 of 475





PHARMACEUTICAL 2022



ABBOTT LABORATORIES Rank 20 of 475



The relative strengths and weaknesses of ABBOTT LABORATORIES are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ABBOTT LABORATORIES compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 435% points. The greatest weakness of ABBOTT LABORATORIES is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 149% points.

The company's Economic Capital Ratio, given in the ranking table, is 222%, being 499% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	24,239,000
Cost of Goods Sold	18,537,000
Intangible Assets	35,970,000
Liabilities, Current	13,105,000
Liabilities, Non-Current	0
Other Assets	6,028,000
Other Compr. Net Income	572,000
Other Expenses	3,720,000
Other Liabilities	0
Other Net Income	319,000
Property and Equipment	8,959,000
Research and Development	2,742,000
Revenues	43,075,000
Selling, General and Administrative Expense	11,324,000

Output Variable	Value in 1000 USD
Assets	75,196,000
Liabilities	13,105,000
Expenses	36,323,000
Stockholders Equity	62,091,000
Net Income	7,071,000
Comprehensive Net Income	7,357,000
Economic Capital Ratio	222%